{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:29:56Z","timestamp":1772166596070,"version":"3.50.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,29]],"date-time":"2021-03-29T00:00:00Z","timestamp":1616976000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,3,29]],"date-time":"2021-03-29T00:00:00Z","timestamp":1616976000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Res Ther"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hepatic fibrosis is a common complication in transfusion-dependent thalassemia patients. Data on the co-transplantation of mesenchymal stem cells (MSCs) with hematopoietic stem cells (HSCs) in beta-thalassemia major patients are scarce. Therefore, we aimed to evaluate the effect of co-transplantation of bone marrow-derived MSC with HSCs on the liver fibrosis alleviation and transplant outcomes in class III beta-thalassemia major.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Between April 1998 and January 2017, a total of 224 consecutive patients with class III beta-thalassemia major underwent allogeneic HSCT in the Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran. To assess liver fibrotic changes after transplantation, 47 patients participated in the MSC plus HSC group and 30 patients in the HSC only group at the end of the follow-up period. All patients underwent laboratory tests, especially serum ferritin and liver function testing, hepatic T2* MRI, liver biopsy, and FibroScan before and 2\u00a0years after transplantation. Kaplan-Meier curves were derived to determine survival and were compared using the log-rank test. Repeated-measure, mixed-effect linear regression models were used to examine the changes in liver fibrosis over time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The 10-year OS rate was 71.84% in the mesenchymal group and 61.89% in the non-mesenchymal group (\n                      <jats:italic>P<\/jats:italic>\n                      value\u2009=\u20090.294), while the 10-year TFS rate was 63.64% in the mesenchymal group and 52.78% in the non-mesenchymal group (\n                      <jats:italic>P<\/jats:italic>\n                      value\u2009=\u20090.285). No significant difference was observed in the 10-year NRM, rejection rate, ANC engraftment, platelet engraftment, acute GvHD, and chronic GvHD between the two groups. In addition, the results of repeated-measure, mixed-effect linear regression models showed that none of the variables determining hepatic fibrosis had a significant difference between patients receiving MSCs and patients who did not receive MSCs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Based on the results of this study, a single infusion of MSCs at the time of HSCT to patients with class III beta-thalassemia major could not significantly improve the liver fibrosis alleviation and transplantation outcomes, including OS, TFS, TRM, rejection rate, ANC engraftment, platelet engraftment, acute GvHD, and chronic GvHD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13287-021-02242-8","type":"journal-article","created":{"date-parts":[[2021,3,29]],"date-time":"2021-03-29T11:02:57Z","timestamp":1617015777000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["The effect of bone marrow-derived mesenchymal stem cell co-transplantation with hematopoietic stem cells on liver fibrosis alleviation and survival in patients with class III \u03b2-thalassemia major"],"prefix":"10.1186","volume":"12","author":[{"given":"Tahereh","family":"Rostami","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir","family":"Kasaeian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1511-7052","authenticated-orcid":false,"given":"Nasrollah","family":"Maleki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohsen","family":"Nikbakht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azadeh","family":"Kiumarsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyed Mohammad","family":"Tavangar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir Pejman Hashemi","family":"Taheri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seied Asadollah","family":"Mousavi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ardeshir","family":"Ghavamzadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,29]]},"reference":[{"issue":"2","key":"2242_CR1","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/GIM.0b013e3181cd68ed","volume":"12","author":"A Cao","year":"2010","unstructured":"Cao A, Galanello R. Beta-thalassemia. Genet Med. 2010;12(2):61\u201376.","journal-title":"Genet Med"},{"key":"2242_CR2","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/j.1749-6632.2010.05543.x","volume":"1202","author":"A Isgr\u00f2","year":"2010","unstructured":"Isgr\u00f2 A, Gaziev J, Sodani P, Lucarelli G. Progress in hematopoietic stem cell transplantation as allogeneic cellular gene therapy in thalassemia. Ann N Y Acad Sci. 2010;1202:149\u201354.","journal-title":"Ann N Y Acad Sci"},{"issue":"1\u20132","key":"2242_CR3","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1080\/03630260701699912","volume":"32","author":"JC Wood","year":"2008","unstructured":"Wood JC, Ghugre N. Magnetic resonance imaging assessment of excess iron in thalassemia, sickle cell disease and other iron overload diseases. Hemoglobin. 2008;32(1\u20132):85\u201396.","journal-title":"Hemoglobin."},{"issue":"1","key":"2242_CR4","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1182\/asheducation-2017.1.265","volume":"2017","author":"AT Taher","year":"2017","unstructured":"Taher AT, Saliba AN. Iron overload in thalassemia: different organs at different rates. Hematology Am Soc Hematol Educ Program. 2017;2017(1):265\u201371.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"2","key":"2242_CR5","doi-asserted-by":"publisher","first-page":"214","DOI":"10.3324\/haematol.2015.141200","volume":"102","author":"A Srivastava","year":"2017","unstructured":"Srivastava A, Shaji RV. Cure for thalassemia major - from allogeneic hematopoietic stem cell transplantation to gene therapy. Haematologica. 2017;102(2):214\u201323.","journal-title":"Haematologica."},{"key":"2242_CR6","doi-asserted-by":"crossref","unstructured":"Angelucci E, Matthes-Martin S, Baronciani D, Bernaudin F, Bonanomi S, Cappellini MD, et al; EBMT Inborn Error and EBMT Paediatric Working Parties. Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel. Haematologica. 2014;99(5):811\u2013820.","DOI":"10.3324\/haematol.2013.099747"},{"issue":"4","key":"2242_CR7","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/bmt.2015.293","volume":"51","author":"D Baronciani","year":"2016","unstructured":"Baronciani D, Angelucci E, Potschger U, Gaziev J, Yesilipek A, Zecca M, et al. Hemopoietic stem cell transplantation in thalassemia: a report from the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Registry, 2000-2010. Bone Marrow Transplant. 2016;51(4):536\u201341.","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"2242_CR8","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1002\/ajh.24898","volume":"92","author":"G Caocci","year":"2017","unstructured":"Caocci G, Orofino MG, Vacca A, Piroddi A, Piras E, Addari MC, et al. Long-term survival of beta thalassemia major patients treated with hematopoietic stem cell transplantation compared with survival with conventional treatment. Am J Hematol. 2017;92(12):1303\u201310.","journal-title":"Am J Hematol"},{"issue":"2","key":"2242_CR9","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.bbmt.2018.09.026","volume":"25","author":"A Ghavamzadeh","year":"2019","unstructured":"Ghavamzadeh A, Kasaeian A, Rostami T, Kiumarsi A. Comparable outcomes of allogeneic peripheral blood versus bone marrow hematopoietic stem cell transplantation in major thalassemia: a multivariate long-term cohort analysis. Biol Blood Marrow Transplant. 2019;25(2):307\u201312.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"2242_CR10","doi-asserted-by":"publisher","first-page":"667","DOI":"10.7326\/0003-4819-136-9-200205070-00009","volume":"136","author":"P Muretto","year":"2002","unstructured":"Muretto P, Angelucci E, Lucarelli G. Reversibility of cirrhosis in patients cured of thalassemia by bone marrow transplantation. Ann Intern Med. 2002;136(9):667\u201372.","journal-title":"Ann Intern Med"},{"issue":"2","key":"2242_CR11","first-page":"55","volume":"9","author":"A Ghavamzadeh","year":"2015","unstructured":"Ghavamzadeh A, Mirzania M, Kamalian N, Sedighi N, Azimi P. Hepatic iron overload and fibrosis in patients with beta thalassemia major after hematopoietic stem cell transplantation: a pilot study. Int J Hematol Oncol Stem Cell Res. 2015;9(2):55\u20139.","journal-title":"Int J Hematol Oncol Stem Cell Res"},{"issue":"5","key":"2242_CR12","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1136\/adc.86.5.344","volume":"86","author":"CK Li","year":"2002","unstructured":"Li CK, Chik KW, Lam CW, To KF, Yu SC, Lee V, et al. Liver disease in transfusion dependent thalassaemia major. Arch Dis Child. 2002;86(5):344\u20137.","journal-title":"Arch Dis Child"},{"issue":"Suppl 1","key":"2242_CR13","first-page":"29","volume":"12","author":"E Angelucci","year":"1993","unstructured":"Angelucci E, Baronciani D, Lucarelli G, Giardini C, Galimberti M, Polchi P, et al. Liver iron overload and liver fibrosis in thalassemia. Bone Marrow Transplant. 1993;12(Suppl 1):29\u201331.","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2242_CR14","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1136\/adc.59.1.67","volume":"59","author":"G Jean","year":"1984","unstructured":"Jean G, Terzoli S, Mauri R, Borghetti L, Di Palma A, Piga A, et al. Cirrhosis associated with multiple transfusions in thalassaemia. Arch Dis Child. 1984;59(1):67\u201370.","journal-title":"Arch Dis Child"},{"issue":"3","key":"2242_CR15","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1001\/archpedi.1988.02150030057020","volume":"142","author":"HS Maurer","year":"1988","unstructured":"Maurer HS, Lloyd-Still JD, Ingrisano C, Gonzalez-Crussi F, Honig GR. A prospective evaluation of iron chelation therapy in children with severe beta-thalassemia. A six-year study. Am J Dis Child. 1988;142(3):287\u201392.","journal-title":"Am J Dis Child"},{"issue":"1","key":"2242_CR16","doi-asserted-by":"publisher","first-page":"e2019030","DOI":"10.4084\/mjhid.2019.030","volume":"11","author":"F Pilo","year":"2019","unstructured":"Pilo F, Angelucci E. Iron toxicity and hemopoietic cell transplantation: time to change the paradigm. Mediterr J Hematol Infect Dis. 2019;11(1):e2019030.","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"3","key":"2242_CR17","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1182\/blood.V90.3.994","volume":"90","author":"E Angelucci","year":"1997","unstructured":"Angelucci E, Muretto P, Lucarelli G, Ripalti M, Baronciani D, Erer B, et al. Phlebotomy to reduce iron overload in patients cured of thalassemia by bone marrow transplantation. Italian Cooperative Group for Phlebotomy Treatment of Transplanted Thalassemia Patients. Blood. 1997;90(3):994\u20138.","journal-title":"Blood."},{"issue":"12","key":"2242_CR18","doi-asserted-by":"publisher","first-page":"3905","DOI":"10.1096\/fj.201600433R","volume":"30","author":"D Haldar","year":"2016","unstructured":"Haldar D, Henderson NC, Hirschfield G, Newsome PN. Mesenchymal stromal cells and liver fibrosis: a complicated relationship. FASEB J. 2016;30(12):3905\u201328.","journal-title":"FASEB J"},{"issue":"14","key":"2242_CR19","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1007\/s00018-020-03454-6","volume":"77","author":"XL Fan","year":"2020","unstructured":"Fan XL, Zhang Y, Li X, Fu QL. Mechanisms underlying the protective effects of mesenchymal stem cell-based therapy. Cell Mol Life Sci. 2020;77(14):2771\u201394.","journal-title":"Cell Mol Life Sci"},{"issue":"5","key":"2242_CR20","doi-asserted-by":"publisher","first-page":"626","DOI":"10.3390\/jcm8050626","volume":"8","author":"M Najar","year":"2019","unstructured":"Najar M, Bouhtit F, Melki R, et al. Mesenchymal stromal cell-based therapy: new perspectives and challenges. J Clin Med. 2019;8(5):626.","journal-title":"J Clin Med"},{"key":"2242_CR21","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1146\/annurev-bioeng-070909-105309","volume":"12","author":"B Parekkadan","year":"2010","unstructured":"Parekkadan B, Milwid JM. Mesenchymal stem cells as therapeutics. Annu Rev Biomed Eng. 2010;12:87\u2013117.","journal-title":"Annu Rev Biomed Eng"},{"key":"2242_CR22","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41536-019-0083-6","volume":"4","author":"MF Pittenger","year":"2019","unstructured":"Pittenger MF, Discher DE, P\u00e9ault BM, Phinney DG, Hare JM, Caplan AI. Mesenchymal stem cell perspective: cell biology to clinical progress. NPJ Regen Med. 2019;4:22.","journal-title":"NPJ Regen Med"},{"issue":"13\u201314","key":"2242_CR23","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.lfs.2009.08.003","volume":"85","author":"YJ Chang","year":"2009","unstructured":"Chang YJ, Liu JW, Lin PC, Sun LY, Peng CW, Luo GH, et al. Mesenchymal stem cells facilitate recovery from chemically induced liver damage and decrease liver fibrosis. Life Sci. 2009;85(13\u201314):517\u201325.","journal-title":"Life Sci"},{"issue":"4","key":"2242_CR24","first-page":"459","volume":"10","author":"M Mohamadnejad","year":"2007","unstructured":"Mohamadnejad M, Alimoghaddam K, Mohyeddin-Bonab M, Bagheri M, Bashtar M, Ghanaati H, et al. Phase 1 trial of autologous bone marrow mesenchymal stem cell transplantation in patients with decompensated liver cirrhosis. Arch Iran Med. 2007;10(4):459\u201366.","journal-title":"Arch Iran Med"},{"issue":"10","key":"2242_CR25","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1111\/liv.12228","volume":"33","author":"M Mohamadnejad","year":"2013","unstructured":"Mohamadnejad M, Alimoghaddam K, Bagheri M, Ashrafi M, Abdollahzadeh L, Akhlaghpoor S, et al. Randomized placebo-controlled trial of mesenchymal stem cell transplantation in decompensated cirrhosis. Liver Int. 2013;33(10):1490\u20136.","journal-title":"Liver Int"},{"issue":"10","key":"2242_CR26","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1097\/MEG.0b013e32832a1f6c","volume":"21","author":"P Kharaziha","year":"2009","unstructured":"Kharaziha P, Hellstr\u00f6m PM, Noorinayer B, Farzaneh F, Aghajani K, Jafari F, et al. Improvement of liver function in liver cirrhosis patients after autologous mesenchymal stem cell injection: a phase I-II clinical trial. Eur J Gastroenterol Hepatol. 2009;21(10):1199\u2013205.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"3","key":"2242_CR27","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1002\/hep.24434","volume":"54","author":"L Peng","year":"2011","unstructured":"Peng L, Xie DY, Lin BL, Liu J, Zhu HP, Xie C, et al. Autologous bone marrow mesenchymal stem cell transplantation in liver failure patients caused by hepatitis B: short-term and long-term outcomes. Hepatology. 2011;54(3):820\u20138.","journal-title":"Hepatology."},{"issue":"10","key":"2242_CR28","doi-asserted-by":"publisher","first-page":"725","DOI":"10.5966\/sctm.2012-0034","volume":"1","author":"M Shi","year":"2012","unstructured":"Shi M, Zhang Z, Xu R, Lin H, Fu J, Zou Z, et al. Human mesenchymal stem cell transfusion is safe and improves liver function in acute-on-chronic liver failure patients. Stem Cells Transl Med. 2012;1(10):725\u201331.","journal-title":"Stem Cells Transl Med"},{"issue":"3","key":"2242_CR29","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1007\/s12015-011-9322-y","volume":"8","author":"M El-Ansary","year":"2012","unstructured":"El-Ansary M, Abdel-Aziz I, Mogawer S, Abdel-Hamid S, Hammam O, Teaema S, et al. Phase II trial: undifferentiated versus differentiated autologous mesenchymal stem cells transplantation in Egyptian patients with HCV induced liver cirrhosis. Stem Cell Rev Rep. 2012;8(3):972\u201381.","journal-title":"Stem Cell Rev Rep"},{"issue":"Suppl 2","key":"2242_CR30","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/j.1440-1746.2011.07024.x","volume":"27","author":"Z Zhang","year":"2012","unstructured":"Zhang Z, Lin H, Shi M, Xu R, Fu J, Lv J, et al. Human umbilical cord mesenchymal stem cells improve liver function and ascites in decompensated liver cirrhosis patients. J Gastroenterol Hepatol. 2012;27(Suppl 2):112\u201320.","journal-title":"J Gastroenterol Hepatol"},{"issue":"3","key":"2242_CR31","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/scrt459","volume":"5","author":"H Salama","year":"2014","unstructured":"Salama H, Zekri AR, Medhat E, Al Alim SA, Ahmed OS, Bahnassy AA, et al. Peripheral vein infusion of autologous mesenchymal stem cells in Egyptian HCV-positive patients with end-stage liver disease. Stem Cell Res Ther. 2014;5(3):70.","journal-title":"Stem Cell Res Ther"},{"issue":"9","key":"2242_CR32","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1111\/1756-185X.13015","volume":"20","author":"J Liang","year":"2017","unstructured":"Liang J, Zhang H, Zhao C, Wang D, Ma X, Zhao S, et al. Effects of allogeneic mesenchymal stem cell transplantation in the treatment of liver cirrhosis caused by autoimmune diseases. Int J Rheum Dis. 2017;20(9):1219\u201326.","journal-title":"Int J Rheum Dis"},{"issue":"7","key":"2242_CR33","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/NEJM199002153220701","volume":"322","author":"G Lucarelli","year":"1990","unstructured":"Lucarelli G, Galimberti M, Polchi P, et al. Bone marrow transplantation in patients with thalassemia. N Engl J Med. 1990;322(7):417\u201321.","journal-title":"N Engl J Med"},{"issue":"6","key":"2242_CR34","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1182\/blood.V80.6.1603.1603","volume":"80","author":"G Lucarelli","year":"1992","unstructured":"Lucarelli G, Galimberti M, Polchi P, et al. Bone marrow transplantation in adult thalassemia. Blood. 1992;80(6):1603\u20137.","journal-title":"Blood."},{"issue":"1","key":"2242_CR35","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1532-429X-16-40","volume":"16","author":"MW Garbowski","year":"2014","unstructured":"Garbowski MW, Carpenter JP, Smith G, Roughton M, Alam MH, He T, et al. Biopsy-based calibration of T2* magnetic resonance for estimation of liver iron concentration and comparison with R2 Ferriscan. J Cardiovasc Magn Reson. 2014;16(1):40.","journal-title":"J Cardiovasc Magn Reson"},{"issue":"3","key":"2242_CR36","first-page":"828","volume":"51","author":"L Cast\u00e9ra","year":"2010","unstructured":"Cast\u00e9ra L, Foucher J, Bernard PH, Carvalho F, Allaix D, Merrouche W, et al. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology. 2010;51(3):828\u201335.","journal-title":"Hepatology."},{"issue":"8","key":"2242_CR37","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1002\/ajh.21752","volume":"85","author":"M Fraquelli","year":"2010","unstructured":"Fraquelli M, Cassinerio E, Roghi A, Rigamonti C, Casazza G, Colombo M, et al. Transient elastography in the assessment of liver fibrosis in adult thalassemia patients. Am J Hematol. 2010;85(8):564\u20138.","journal-title":"Am J Hematol"},{"issue":"2","key":"2242_CR38","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1002\/hep.510240201","volume":"24","author":"P Bedossa","year":"1996","unstructured":"Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996;24(2):289\u201393.","journal-title":"Hepatology"},{"issue":"2","key":"2242_CR39","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/0002-9343(80)90380-0","volume":"69","author":"HM Shulman","year":"1980","unstructured":"Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69(2):204\u201317.","journal-title":"Am J Med"},{"issue":"4","key":"2242_CR40","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1097\/00007890-197410000-00001","volume":"18","author":"H Glucksberg","year":"1974","unstructured":"Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18(4):295\u2013304.","journal-title":"Transplantation."},{"issue":"4","key":"2242_CR41","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1001\/jama.2015.19394","volume":"315","author":"MA Detry","year":"2016","unstructured":"Detry MA, Ma Y. Analyzing repeated measurements using mixed models. JAMA. 2016;315(4):407\u20138.","journal-title":"JAMA."},{"issue":"8","key":"2242_CR42","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.3324\/haematol.12554","volume":"93","author":"V Di Marco","year":"2008","unstructured":"Di Marco V, Capra M, Gagliardotto F, Borsellino Z, Cabibi D, Barbaria F, et al. Liver disease in chelated transfusion-dependent thalassemics: the role of iron overload and chronic hepatitis C. Haematologica. 2008;93(8):1243\u20136.","journal-title":"Haematologica."},{"issue":"10","key":"2242_CR43","first-page":"1179","volume":"89","author":"D Prati","year":"2004","unstructured":"Prati D, Maggioni M, Milani S, Cerino M, Cianciulli P, Coggi G, et al. Clinical and histological characterization of liver disease in patients with transfusion-dependent beta-thalassemia. A multicenter study of 117 cases. Haematologica. 2004;89(10):1179\u201386.","journal-title":"Haematologica."},{"issue":"1","key":"2242_CR44","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/S1665-2681(19)31385-7","volume":"12","author":"MS Elalfy","year":"2013","unstructured":"Elalfy MS, Esmat G, Matter RM, Abdel Aziz HE, Massoud WA. Liver fibrosis in young Egyptian beta-thalassemia major patients: relation to hepatitis C virus and compliance with chelation. Ann Hepatol. 2013;12(1):54\u201361.","journal-title":"Ann Hepatol"},{"issue":"5","key":"2242_CR45","doi-asserted-by":"publisher","first-page":"580","DOI":"10.3904\/kjim.2015.30.5.580","volume":"30","author":"YW Eom","year":"2015","unstructured":"Eom YW, Shim KY, Baik SK. Mesenchymal stem cell therapy for liver fibrosis. Korean J Intern Med. 2015;30(5):580\u20139.","journal-title":"Korean J Intern Med"},{"key":"2242_CR46","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s13578-020-00480-6","volume":"10","author":"X Yang","year":"2020","unstructured":"Yang X, Meng Y, Han Z, Ye F, Wei L, Zong C. Mesenchymal stem cell therapy for liver disease: full of chances and challenges. Cell Biosci. 2020;10:123.","journal-title":"Cell Biosci"},{"key":"2242_CR47","doi-asserted-by":"publisher","unstructured":"Rostami T, Maleki N, Kasaeian A, Nikbakht M, Kiumarsi A, Asadollah Mousavi S, Ghavamzadeh A. Co-transplantation of bone marrow-derived mesenchymal stem cells with hematopoietic stem cells does not improve transplantation outcome in class III beta-thalassemia major: A prospective cohort study with long-term follow-up. Pediatr Transplant. 2020;e13905. https:\/\/doi.org\/10.1111\/petr.13905. Epub ahead of print.","DOI":"10.1111\/petr.13905"},{"issue":"1","key":"2242_CR48","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1073\/pnas.66.1.65","volume":"66","author":"I Hellstr\u00f6m","year":"1970","unstructured":"Hellstr\u00f6m I, Hellstr\u00f6m KE, Storb R, Thomas ED. Colony inhibition of fibroblasts from chimeric dogs mediated by the dogs\u2019 own lymphocytes and specifically abrogated by their serum. Proc Natl Acad Sci U S A. 1970;66(1):65\u201371.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"2242_CR49","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1097\/00007890-197108000-00001","volume":"12","author":"A Friedenstein","year":"1971","unstructured":"Friedenstein A, Kuralesova AI. Osteogenic precursor cells of bone marrow in radiation chimeras. Transplantation. 1971;12(2):99\u2013108.","journal-title":"Transplantation."},{"key":"2242_CR50","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3389\/fimmu.2012.00297","volume":"3","author":"E Eggenhofer","year":"2012","unstructured":"Eggenhofer E, Benseler V, Kroemer A, et al. Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion. Front Immunol. 2012;3:297.","journal-title":"Front Immunol"},{"issue":"4","key":"2242_CR51","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1097\/00007890-197404000-00001","volume":"17","author":"AJ Friedenstein","year":"1974","unstructured":"Friedenstein AJ, Chailakhyan RK, Latsinik NV, Panasyuk AF, Keiliss-Borok IV. Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo. Transplantation. 1974;17(4):331\u201340.","journal-title":"Transplantation."},{"key":"2242_CR52","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/S0074-7696(08)60092-3","volume":"47","author":"AJ Friedenstein","year":"1976","unstructured":"Friedenstein AJ. Precursor cells of mechanocytes. Int Rev Cytol. 1976;47:327\u201359.","journal-title":"Int Rev Cytol"},{"key":"2242_CR53","first-page":"19","volume":"25","author":"AJ Friedenstein","year":"1980","unstructured":"Friedenstein AJ. Stromal mechanisms of bone marrow: cloning in vitro and retransplantation in vivo. Haematol Blood Transfus. 1980;25:19\u201329.","journal-title":"Haematol Blood Transfus"},{"issue":"1","key":"2242_CR54","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1159\/000496809","volume":"46","author":"S Elgaz","year":"2019","unstructured":"Elgaz S, Ku\u00e7i Z, Ku\u00e7i S, B\u00f6nig H, Bader P. Clinical use of mesenchymal stromal cells in the treatment of acute graft-versus-host disease. Transfus Med Hemother. 2019;46(1):27\u201334.","journal-title":"Transfus Med Hemother"},{"issue":"6","key":"2242_CR55","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1002\/eji.200738129","volume":"38","author":"D Polchert","year":"2008","unstructured":"Polchert D, Sobinsky J, Douglas G, Kidd M, Moadsiri A, Reina E, et al. IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur J Immunol. 2008;38(6):1745\u201355.","journal-title":"Eur J Immunol"},{"key":"2242_CR56","doi-asserted-by":"crossref","unstructured":"Tisato V, Naresh K, Girdlestone J, Navarrete C, Dazzi F. Mesenchymal stem cells of cord blood origin are effective at preventing but not treating graft-versus-host disease. Leukemia. 2007;21(9):1992\u20139.","DOI":"10.1038\/sj.leu.2404847"},{"key":"2242_CR57","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.3389\/fimmu.2020.01338","volume":"11","author":"TS Cheung","year":"2020","unstructured":"Cheung TS, Bertolino GM, Giacomini C, Bornh\u00e4user M, Dazzi F, Galleu A. Mesenchymal stromal cells for graft versus host disease: mechanism-based biomarkers. Front Immunol. 2020;11:1338.","journal-title":"Front Immunol"},{"issue":"2","key":"2242_CR58","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s00277-017-3181-9","volume":"97","author":"A Ghavamzadeh","year":"2018","unstructured":"Ghavamzadeh A, Sotoudeh M, Hashemi Taheri AP, Alimoghaddam K, Pashaiefar H, Jalili M, et al. Liver fibrosis alleviation after co-transplantation of hematopoietic stem cells with mesenchymal stem cells in patients with thalassemia major. Ann Hematol. 2018;97(2):327\u201334.","journal-title":"Ann Hematol"},{"issue":"7","key":"2242_CR59","doi-asserted-by":"publisher","first-page":"2764","DOI":"10.1182\/blood-2007-04-087056","volume":"110","author":"LM Ball","year":"2007","unstructured":"Ball LM, Bernardo ME, Roelofs H, et al. Cotransplantation of ex vivo\u2013expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation. Blood. 2007;110(7):2764\u20137.","journal-title":"Blood."},{"key":"2242_CR60","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1476-9255-2-8","volume":"2","author":"JM Ryan","year":"2005","unstructured":"Ryan JM, Barry FP, Murphy JM, Mahon BP. Mesenchymal stem cells avoid allogeneic rejection. J Inflamm (Lond). 2005;2:8.","journal-title":"J Inflamm (Lond)"},{"issue":"8","key":"2242_CR61","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1038\/sj.leu.2404777","volume":"21","author":"K Le Blanc","year":"2007","unstructured":"Le Blanc K, Samuelsson H, Gustafsson B, Remberger M, Sundberg B, Arvidson J, et al. Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia. 2007;21(8):1733\u20138.","journal-title":"Leukemia."}],"container-title":["Stem Cell Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-021-02242-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13287-021-02242-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-021-02242-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,29]],"date-time":"2021-03-29T11:11:29Z","timestamp":1617016289000},"score":1,"resource":{"primary":{"URL":"https:\/\/stemcellres.biomedcentral.com\/articles\/10.1186\/s13287-021-02242-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,29]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2242"],"URL":"https:\/\/doi.org\/10.1186\/s13287-021-02242-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-178042\/v1","asserted-by":"object"}]},"ISSN":["1757-6512"],"issn-type":[{"value":"1757-6512","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,29]]},"assertion":[{"value":"2 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical issues (including plagiarism, informed consent, misconduct, data fabrication and\/or falsification, double publication and\/or submission, redundancy) have been completely observed by the authors. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent was obtained from all subjects whose clinical data has been used and the ones included in the study for interviews in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"213"}}